Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 11/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.43 |
| ▸ | NPY4R | P50391 | 2/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24094770 | 0.93 | SIRT2 (0.44) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL14887385 | 0.92 | SIRT2 (0.43) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL17236056 | 0.92 | SIRT2 (0.43) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL10051252 | 0.92 | SIRT2 (0.43) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL16455129 | 0.92 | SIRT2 (0.43) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL18823483 | 0.92 | SIRT2 (0.43) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL20442348 | 0.92 | SIRT2 (0.45) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL19456862 | 0.91 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL24224697 | 0.91 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL15606256 | 0.91 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5NPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346968-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230340020-A1 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP | BICYCLETX LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-11730819-B2 | Peptide derivatives having novel linkage structures | BICYCLETX LIMITED (GB) | 2023-08-22 | — | — | US | disclosed |
| US-20200316209-A1 | PEPTIDE DERIVATIVES HAVING NOVEL LINKAGE STRUCTURES | BICYCLETX LIMITED (GB) | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340020-A1 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP | MMP11, MMP3, ANPEP | SIRT2 4168/4885SIRT1 4417/4885SIRT3 3297/4885 |
| US-20200316209-A1 | PEPTIDE DERIVATIVES HAVING NOVEL LINKAGE STRUCTURES | DNPEP, LNPEP, SPPL2B | SIRT2 2464/4885SIRT1 2843/4885SIRT3 1831/4885 |
| US-11730819-B2 | Peptide derivatives having novel linkage structures | DNPEP, LNPEP, ANPEP | SIRT2 2366/4885SIRT1 2722/4885SIRT3 1702/4885 |
| US-20230346968-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | IGSF11, CD2BP2, PA2G4 | SIRT2 2850/4885SIRT1 3931/4885SIRT3 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.